Sign in Subscribe
Pediatrics

Immune Checkpoint Inhibitors Show Promise in Pediatric Liver Cancer Treatment

Strategic Insights

— 1 min read

Researchers at the First Affiliated Hospital of Gannan Medical University in Jiangxi, People's Republic of China, have reported two cases of pathologically confirmed pediatric hepatocellular carcinoma (HCC) treated with immune checkpoint inhibitors (ICIs). The study, published in Frontiers in Oncology, highlights the potential of ICIs in pediatric HCC treatment, despite the lack of standard options for unresectable/metastatic disease.

Key Takeaways:

  • The study reports on two cases of pediatric HCC treated with ICIs, with the first patient undergoing transhepatic arterial chemoembolization (TACE) and sintilimab immunotherapy, and the second patient receiving oral sorafenib-targeted therapy followed by sequential immunotherapy with tirilizumab and sintilimab.
  • The only adverse reaction of grade 3 or higher in both patients was skin rashes.
  • The study emphasizes the need for ongoing prospective studies to determine the clinical role of ICIs in pediatric HCC and to establish robust evidence of their efficacy and safety.
  • The authors highlight the importance of cautious application of ICIs in pediatric HCC patients until further evidence emerges.
  • The study provides a comprehensive case report and review of the literature on pediatric HCC treatment, underscoring the need for more research in this area.

Statistics:

  • 2 patients with pathologically confirmed pediatric HCC were treated with ICIs.
  • 1 patient underwent TACE and sintilimab immunotherapy.
  • 1 patient received oral sorafenib-targeted therapy followed by sequential immunotherapy with tirilizumab and sintilimab.
  • 2 patients experienced skin rashes as an adverse reaction of grade 3 or higher.
  • The study emphasizes the need for ongoing prospective studies to determine the clinical role of ICIs in pediatric HCC.

Sources:

  • Frontiers in Oncology (2025)
  • NewsRx: Researchers at First Affiliated Hospital of Gannan Medical University Have Reported New Data on Liver Cancer (Safety and clinical efficacy of immune checkpoint inhibitors in pediatric hepatocellular carcinoma: a case report and review of the ...). Immunotherapy Weekly. September 17, 2025; p 986.

Read more